As part of its stock-based compensation package, International Electronics (IE) granted 14 million stock appreciation rights (SARS) to top officers on January 1, 2024. At exercise, holders of the SARS are entitled to receive stock equal in value to the excess of the market price at exercise over the share price at the date of grant. The SARS cannot be exercised until the end of 2027 (vesting date) and expire at the end of 2029. The $1 par common shares have a market price of $46 per share on the grant date. The fair value of the SARS, estimated by an appropriate option pricing model, is $3 per SAR at January 1, 2024. The fair value re-estimated at December 31, 2024, 2025, 2026, 2027, and 2028, is $4, $3, $4, $2.50, and $3, respectively. All recipients are expected to remain employed through the vesting date. Required: 1-a.Will the SARS be reported as debt or as equity? 1-b to 4.Prepare the appropriate journal entries pertaining to the SARS on January 1, 2024 and December 31, 2024-December 31, 2027. Assuming the SARS remain unexercised on December 31, 2028, prepare the appropriate entry. Prepare the entry when the SARS are exercised on June 6, 2029, when the share price is $50. Prepare the appropriate journal entries pertaining to the SARS on January 1, 2024 and December 31, 2024-December 31, 2027. Assuming the SARS remain unexercised on December 31, 2028, prepare the appropriate entry. Prepare the entry when the SARS are exercised on June 6, 2029, when the share price is $50. Note: If no entry is required for a transaction/event, select "No journal entry required" in the first account field. Enter your answers in millions rounded to 2 decimal places (i.e., 5,500,000 should be entered as 5.50). Show less A Debit Credit No Date General Journal 1 January 01, 2024 No journal entry required 2 December 31, 202 Compensation expense Paid-in capital-SAR plan 10.50 10.50 3 December 31, 202 Compensation expense 10.50 Paid-in capital-SAR plan 10.50 4 December 31, 202 Compention expense 10.50 Paid-in capital-SAR plan 10.50 5 December 31, 202 Compensation expense 10.50 Paid-in capital-SAR plan 10.50 6 December 31, 2021 No journal entry required 7 June 06, 2029 Paid-in capital-SAR plan Common stock Paid-in capital-excess of par Journal entry worksheet < 2 3 5 7 Record any necessary entry on June 6, 2029 when the SARS are exercised and the share price is $50. Note: Enter debits before credits. Date General Journal Debit Credit June 06, 2029 Paid-in capital - SAR plan Common stock Paid-in capital - excess of par